Company intelligence / Profile preview

YUN

Niel, Antwerpen/Vlaanderen, Belgiumyun-berlin.com ↗

Ownership: Private
Development stage: Other

Overview

YUN has developed a proprietary platform enabling stable incorporation of live probiotic bacteria into creams and sprays. Clinical studies have demonstrated efficacy in restoring healthy skin flora and treating common conditions such as acne. The approach aims to reduce antibiotic use by leveraging beneficial microbes instead of antimicrobials. The company collaborates with leading academic experts in Europe.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Live biotherapeutic product therapy (live probiotics in creams and sprays)Microbial therapy (probiotic strains)Device (patented aerosol technology for delivery)
Industry: Biotech

Drug pipeline

3 assets

YUN BBY

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

University of AntwerpFlemish government innovation agencies Vlaio/IWT/EWI

Beyond the preview

Go deeper on YUN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YUN.

Explore the full profile